Hysolv Animal Health has announced the launch of Salmovac 440, a new live salmonella vaccine for poultry which the company claims gives earlier, stronger and longer-lasting immunity than other salmonella vaccines.
The vaccine is given orally through the water supply in a three-dose regime that protects against Salmonella Enteritidis (SE) and Salmonella Typhimurium (ST). It also protects against other SE strains and the newly-emerging monophasic Salmonella Typhimurium strains.
Hysolv says the advantage for farmers is that the vaccine strain is robust and can survive in more hostile conditions. It therefore remains effective where the water delivery system is less than ideal.
The first dose is administered from Day 1 followed by a second dose at six weeks and a third as early as 11 weeks. Salmovac 440 protects chicks after six days and remains effective for up to 63 weeks after the third vaccination, providing an extra four weeks of protection.
Hysolv says another important benefit to egg producers is that the earlier final vaccination at 11 weeks means that the birds can be moved into the laying house as early as 16 weeks old if required — a significant management advantage on some farms.
During the development of the vaccine it was found that the third live vaccination tended to ‘shut down’ any prolonged shedding of the vaccine strain. This, coupled with the earlier vaccination at 11 weeks, helps solve the issue of the vaccine strain being found at transfer to the layer house. Dr Daniel Windhorst, salmonella vaccine specialist with IDT Biologika, said: "If any should be found, the new PCR (Polymerase Chain Reaction) test shrinks the testing time to just two to three hours."
Daniel added: "Although the UK has one of the lowest percentages of salmonella in its flocks, almost one-third of cases were of S Typhimurium. In most continental countries the percentage is much higher, so the extra cover provided by this vaccine is important."
Salmovac 440 has been approved for use by the British Egg Industry Council, which administers the Lion Code.
IDT Biologika and Hysolv Animal Health have announced the publication of A guide to oedema disease in pigs, a six-page booklet written to help pig producers understand the causes, effects and treatment of this ailment.
Author, F Javier Salquero, an independent European veterinary specialist in porcine health management, outlines the risk factors, how to identify oedema disease, current methods of treatment and prevention strategies. The booklet includes a table of the symptoms to be expected in new-born, suckling, post-weaned, grower-finishers and adult pigs.
The booklet concludes that treatment of oedema disease is generally unsuccessful and most pigs showing clinical signs die. However, preventive measures include adjustment of feeding regimes, stress reduction, improved biosecurity and vaccination.
Hysolv director, Richard Brealey said: "Oedema is a widespread, lethal and economically-important disease in pigs, and there is increasing pressure in Europe to reduce the use of antibiotics in livestock. Fully understanding this disease is a first step to control and prevention".
Hysolv says a German calculation showed a reduction in margin of 83 Euros (£74) per sow, equivalent to 41,000 Euros (£32,500) for a 500-sow herd, due to oedema.
The booklet — printed on heavy duty glossy card – suitable for use in piggeries — is available, free, by visiting the Hysolv website: www.hysolv.co.uk
Hysolv Animal Health has announced that it is offering a free swine flu laboratory diagnostic service to veterinary surgeons in the UK and Ireland.
The company will supply kits to veterinary surgeons with which to take samples from pig herds they suspect are infected with swine flu. The samples, nasal swabs or blood, will be sent direct to Germany where vaccine and biological company IDT Biologika is using a special facility to detect which viruses or antibodies against certain serotypes are present.
The virological tests will be conducted by the Institute for Virus Diagnostics, part of the Federal Research Institute for Animal Health. Antibody titres against H1N1, H1N2, H3N2, panH1N1 and panH1N2 will be looked for. Hysolv says these tests, including histopathology, can provide the only conclusive proof of influenza infection.
Results from the test — which would normally cost 230 Euros (about £185) to conduct — will be available within a week. IDT is believed to be the first company offering this type of test.
According to the company, the PCR test — from nasal swabs — is much more precise than previous testing regimes and will identify and type circulating strains as well as emerging strains.
Hysolv says that when swine flu strikes a farm, the signs seen are no longer just typically flu-like but a show whole range including fever, coughing, dyspnoea as well as returns to oestrus and abortions in sows. These may be in combination and concurrent with other diseases which makes accurate diagnosis difficult.
IDT will be offering the newly-branded vaccine Respiporc Flu 3 where the veterinary surgeon feels vaccination in indicated.
Hysolv director Richard Brealey said: “IDT is raising the bar in flu testing and this is a significant advance on what has been done in the past. In 2014 one-third of 1353 nasal swabs sent for testing proved positive for swine flu in Germany. In the UK the samples will help give an insight into the epidemiological status quo of the national pig herd.”